arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2010--5-arthyper-1488Research ArticleКЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯCLINICAL TRIALSТрудности леченияартериальной гипертензии у женщин.Возможности антагонистов рецепторов кангиотензину IIProblems in antihypertensivetreatment in women: Possibilities of angiotensin IIreceptor antagonismДрапкинаО. М.DrapkinaO. M.drapkina@bk.ruПервый Московский государственный медицинский университет им. И.М. СеченоваРоссияI.M. Sechenov First Moscow State Medical University, MoscowRussian Federation201028102010165498503Copyright © Драпкина О.М., 20102010Драпкина О.М.Drapkina O.M.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/1488

Артериальная гипертензия продолжает оставаться проблемой XXI века в кардиологии. Существуют особенности течения артериальной гипертензии у женщин, что диктует необходимость индивидуального подхода в подборе для них антигипертензивной терапии. Важной характеристикой антигипертензивного препарата в данном случае выступает не только высокая эффективность, но и метаболическая нейтральность. Такими качествами обладают антагонисты рецепторов к ангиотензину II, которые все шире применяются в рутинной клинической практике.

Arterial hypertension is one of the most urgent problems in cardiology in the XXI century. Individual approach for antihypertensive treatment is essential in hypertensive women due to the peculiarities of the disease. Both high efficiency and metabolic neutrality are rather important, and angiotensin II receptor antagonists demonstrate both of these properties.

артериальная гипертензияметаболический синдромантагонисты рецепторов к ангиотензину IIarterial hypertensionmetabolic syndromeangiotensin II receptor antagonistsReferencesЧазов Е.И., Чазова И.Е. (ред.). Руководство по артериальной гипертонии. - М., 2005. - 734 с.Чазов Е.И., Чазова И.Е. (ред.). Руководство по артериальной гипертонии. - М., 2005. - 734 с.Недогода С.В. Особенности патогенеза и лечения АГ у женщин // Проблемы женского здоровья. - 2007. - № 1. - C. 47-57.Недогода С.В. Особенности патогенеза и лечения АГ у женщин // Проблемы женского здоровья. - 2007. - № 1. - C. 47-57.Lawes C.M.M., Vander Hoom S., Law M.R., Elliott P., MacMahon S., Rodgers A. Blood pressure and the global burder of disease 2000. Part I: Estimates of blood pressure levels // J. Hypertens. - 2006. - Vol. 24, № 3. - P. 413-422.Lawes C.M.M., Vander Hoom S., Law M.R., Elliott P., MacMahon S., Rodgers A. Blood pressure and the global burder of disease 2000. Part I: Estimates of blood pressure levels // J. Hypertens. - 2006. - Vol. 24, № 3. - P. 413-422.Braunwald E. (Ed.). Braunwald's heart disease: a textbook of cardiovascular medicine. - 8th ed. - 2007. - 1956 p.Braunwald E. (Ed.). Braunwald's heart disease: a textbook of cardiovascular medicine. - 8th ed. - 2007. - 1956 p.Wenger N.K., Collins P. Women & heart disease. - 2nd ed. - 2005. - P. 363-364.Wenger N.K., Collins P. Women & heart disease. - 2nd ed. - 2005. - P. 363-364.Zanchetti A., Facchetti R., Cesana G.C., Modena G.M., Pirrelli A., Sega R. Menopause-related blood pressure increase and its relationship to age and body mass index: the SIMONA epidemiological study // J. Hypertens. - 2005. - Vol. 23, № 12. - P. 2269-2276.Zanchetti A., Facchetti R., Cesana G.C., Modena G.M., Pirrelli A., Sega R. Menopause-related blood pressure increase and its relationship to age and body mass index: the SIMONA epidemiological study // J. Hypertens. - 2005. - Vol. 23, № 12. - P. 2269-2276.Grodstein F., Manson J.E., Colditz G.A., Willett W.C., Speizer F.E., Stampfer M.J. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease // Ann. Intern. Med. - 2000. - Vol. 133, № 12. - P. 933-941.Grodstein F., Manson J.E., Colditz G.A., Willett W.C., Speizer F.E., Stampfer M.J. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease // Ann. Intern. Med. - 2000. - Vol. 133, № 12. - P. 933-941.Farguhar C.M., Marjioribanks J., Lethaby A., Lamberts Q., Suckling J.A. The Cochrane HT Study Group. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane database of Systematic Reviews 2005. Issue 3. Art No CD004143. DOI 10.1002/1465868. CD004143.pub2.MA.Farguhar C.M., Marjioribanks J., Lethaby A., Lamberts Q., Suckling J.A. The Cochrane HT Study Group. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane database of Systematic Reviews 2005. Issue 3. Art No CD004143. DOI 10.1002/1465868. CD004143.pub2.MA.Warner K.K., Visconti J.A., Tschampel M.M. Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema // Ann. Pharmacother. - 2000. - Vol. 34, № 4. - P. 526.Warner K.K., Visconti J.A., Tschampel M.M. Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema // Ann. Pharmacother. - 2000. - Vol. 34, № 4. - P. 526.Coca A., Calvo C., Garsia-Puig J. et al. A multicentral, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, assessed by ambulatory blood pressure monitoring: the MARAVEL study // Clin. Ther. - 2002. -Vol. 24, № 1. - P. 126-138.Coca A., Calvo C., Garsia-Puig J. et al. A multicentral, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, assessed by ambulatory blood pressure monitoring: the MARAVEL study // Clin. Ther. - 2002. -Vol. 24, № 1. - P. 126-138.Rodby R.A., Rohde R.D., Clarke W.R. et al. The Irbesartan Type II Diabetic NephropathyTrial: study design and baseline patient characteristics // Nephrol. Dial. Transplant. - 2000. - Vol. 15, № 4. - P. 487-497.Rodby R.A., Rohde R.D., Clarke W.R. et al. The Irbesartan Type II Diabetic NephropathyTrial: study design and baseline patient characteristics // Nephrol. Dial. Transplant. - 2000. - Vol. 15, № 4. - P. 487-497.Sugimoto K., Qi N.R., Kazdova L., Pravenec M., Ogihara T., Kurtz T.W. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis // Hypertension. - 2006. - Vol. 47, № 5. - P. 1003.Sugimoto K., Qi N.R., Kazdova L., Pravenec M., Ogihara T., Kurtz T.W. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis // Hypertension. - 2006. - Vol. 47, № 5. - P. 1003.Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial // Lancet. - 2004. - Vol. 363, № 9426. - P. 2022-2031.Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial // Lancet. - 2004. - Vol. 363, № 9426. - P. 2022-2031.MacMahon S. Blood pressure lowering treatment trialists' collaboration - second cycle of analyses. Program and abstract of the 13th European Meeting on hypertension (June 13-17, 2003; Milan, Italy). [Электронный ресурс] URL: www.medscape.comMacMahon S. Blood pressure lowering treatment trialists' collaboration - second cycle of analyses. Program and abstract of the 13th European Meeting on hypertension (June 13-17, 2003; Milan, Italy). [Электронный ресурс] URL: www.medscape.comGuidelines for the management of arterial hypertension: The Task Force for the management of arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertens. - 2007. - Vol. 25, № 6. - P. 1105-1187.Guidelines for the management of arterial hypertension: The Task Force for the management of arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertens. - 2007. - Vol. 25, № 6. - P. 1105-1187.Dahlof B., Devereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol // Lancet. - 2002. - Vol. 359, № 9311. - P. 995.Dahlof B., Devereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol // Lancet. - 2002. - Vol. 359, № 9311. - P. 995.Brenner B.M., Cooper M.E., de Zeeuw D. et al. Reduction of endpoints in NIDDM with the angiotensin II antagonist Losartan (RENAAL) // J Renin Angiotensin Aldosterone Syst. - 2000. - Vol. 1, № 4. - P. 328-335.Brenner B.M., Cooper M.E., de Zeeuw D. et al. Reduction of endpoints in NIDDM with the angiotensin II antagonist Losartan (RENAAL) // J Renin Angiotensin Aldosterone Syst. - 2000. - Vol. 1, № 4. - P. 328-335.Iino Y., Hayashi M., Kawamura T. et al. Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension - a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study // Hypertens. Res. - 2004. - Vol. 27, № 1. - P. 21-30.Iino Y., Hayashi M., Kawamura T. et al. Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension - a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study // Hypertens. Res. - 2004. - Vol. 27, № 1. - P. 21-30.Dang A., Zhang Y., Liu G. et al. Effects of losartan and irbesartan on serum uric aсid in hypertensive patients with hyperuricaemia in Chinese population // J. Hum. Hypertens. - 2006. - Vol. 20. - P. 45-49.Dang A., Zhang Y., Liu G. et al. Effects of losartan and irbesartan on serum uric aсid in hypertensive patients with hyperuricaemia in Chinese population // J. Hum. Hypertens. - 2006. - Vol. 20. - P. 45-49.

The authors declare that there are no conflicts of interest present.